⌘K
t
Diaceutics PLC (AIM: DXRX) announced on 5 November 2024 that it will host a virtual Capital Markets Event for analysts and investors. This event is scheduled for Wednesday, 4 December 2024, from 1400-1530 GMT (0900-1030 ET). It will discuss PMx and feature presentations from senior Diaceutics managers and external PMx partners.
| Date | 5 Nov 2024 |
| Time | 07:00:02 |
| Category | Miscellaneous |
| ID | 7065K |
Diaceutics - PMx Capital Markets Webinar - Wednesday, 4 December 2024
Belfast and London, 5 November 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will host a virtual Capital Markets Event for analysts and investors to discuss PMx - a suite of data and knowledge driven services built to revolutionise the commercialisation of precision medicines by removing barriers to access and adoption, on Wednesday, 4 December 2024 at 1400-1530 GMT (0900-1030 ET).
The event will include presentations from senior Diaceutics managers and external PMx partners. The purpose of the event will be to give analysts and investors a deeper insight into the DXRX platform and Diaceutics recently launched PMx service which enables Diaceutics' customers to unlock more value from their product commercialisation and also allows Diaceutics a greater share and participation in this value creation.
To register your interest in attending, please use the following link:
https://us06web.zoom.us/webinar/register/WN_aIuutKaZQrSEYpRDVdr7bg
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.